Educational Notice
This article is for educational purposes only and is not medical advice. Medication decisions, lab interpretation, body-composition concerns, and any exercise or nutrition changes should be discussed with a licensed clinician when appropriate.
Plain-English Summary
For weight-loss efficacy, the current evidence stack is strongest for tirzepatide over semaglutide, while retatrutide looks even more potent in early data but is still investigational as of May 28, 2026.
For muscle or lean-mass retention, the evidence is much less settled.
That distinction matters. The internet often treats these medications like a simple leaderboard. But the weight-loss leaderboard is not the same thing as a muscle-retention leaderboard, and the body-composition data still lag behind the headline scale-weight results.
Key Takeaway
If your main goal is losing fat without giving away too much lean mass, the practical answer is not just “pick the strongest drug.” Right now:
- semaglutide is an established FDA-approved option with strong obesity data
- tirzepatide currently looks stronger than semaglutide for average weight loss
- retatrutide looks very promising in published phase 2 and announced phase 3 obesity results, but it is still not FDA approved
- none of these medications removes the need for protein, resistance training, and slower, higher-quality weight loss
What Is Approved Right Now
As of May 28, 2026:
- semaglutide 2.4 mg weekly is FDA approved for chronic weight management under the Wegovy brand
- tirzepatide is FDA approved for chronic weight management under the Zepbound brand
- retatrutide is not FDA approved and remains investigational
That last point needs to stay clean. Retatrutide may be closer to market than it was a year ago, but “closer” is not the same thing as approved.
Weight-Loss Efficacy: The Ranking Is Clearer Here
Semaglutide has strong obesity efficacy data. In STEP 1, adults with overweight or obesity without diabetes who received semaglutide 2.4 mg weekly had a mean body-weight change of about -14.9% at 68 weeks versus -2.4% with placebo. Source: Wilding et al., NEJM.
Tirzepatide has looked stronger on average in obesity trials. In SURMOUNT-1, adults with obesity or overweight plus a weight-related complication reached mean weight reductions up to about -20.9% at 72 weeks. Source: Jastreboff et al., NEJM.
We also now have a direct semaglutide-versus-tirzepatide obesity comparison. On December 4, 2024, Lilly reported topline SURMOUNT-5 results showing tirzepatide outperformed semaglutide on average percent weight loss and waist reduction in adults with obesity or overweight plus a complication. Source: Lilly SURMOUNT-5 release.
Retatrutide is the wildcard with the biggest upside and the least mature real-world evidence. In the phase 2 obesity trial published in the New England Journal of Medicine, adults receiving retatrutide reached very large mean weight reductions by 48 weeks, with the highest-dose group approaching -24.2%. Source: Jastreboff et al., NEJM.
Then, on May 21, 2026, Lilly announced positive phase 3 TRIUMPH program topline results in obesity, including average weight loss up to -28.3% at 80 weeks in TRIUMPH-1. That is a major signal, but it is still company-reported topline information, not an FDA approval. Source: Lilly retatrutide phase 3 release.
So if your question is purely “Which appears strongest for scale-weight loss?” the current evidence direction is:
- semaglutide: strong
- tirzepatide: stronger
- retatrutide: potentially strongest, but still investigational
Lean Mass And Muscle Retention: This Ranking Is Not Clean Yet
This is where a lot of online discussion gets sloppy.
Obesity trials often report lean mass or fat-free mass, not direct measurements of contractile muscle quality, strength, or long-term function. Those are related, but they are not identical.
The best current takeaway is not that one of these medications is “safe for muscle” while the others are not. The better takeaway is that faster and larger weight loss often includes some lean-mass loss, and the amount that matters clinically depends on age, baseline muscle, protein intake, training, and function.
For tirzepatide, we have better primary body-composition data than many readers realize. In a SURMOUNT-1 body-composition substudy, tirzepatide produced large reductions in body fat while also reducing lean mass, but the overall body-composition shift favored fat loss more than lean loss. Source: SURMOUNT-1 body-composition substudy, PubMed.
For retatrutide, Lilly has also reported a type 2 diabetes substudy showing reductions in liver fat and body fat together with a relative preservation pattern that was more favorable for fat than lean tissue, but the obesity-specific long-term body-composition story is still less mature than the scale-weight story. Source: Lilly retatrutide diabetes substudy release.
For semaglutide, the clinical concern about lean-mass loss is real enough that it should be planned around, but the most useful conclusion is still practical rather than brand-specific: semaglutide can lower lean mass during weight loss, yet that does not automatically translate to a worse functional outcome if protein, resistance training, and pace of loss are handled well.
What We Can Say Honestly Right Now
We can say the following with reasonable confidence:
- tirzepatide currently has stronger obesity weight-loss efficacy data than semaglutide
- retatrutide may outperform both on weight loss if the broader phase 3 data continue to hold up
- retatrutide is still investigational as of May 28, 2026
- all three belong in a conversation about lean-mass protection
- none of the current evidence supports using medication choice as your only muscle-preservation strategy
We cannot yet say with confidence:
- that retatrutide is definitively best for muscle retention
- that tirzepatide is definitively harder or easier on muscle than semaglutide in every real-world case
- that larger headline weight loss automatically means a better body-composition outcome
What To Do With This In Real Life
If your main fear is “I want to lose fat, not become smaller and weaker,” then a better comparison framework is:
- Which medication is most appropriate medically?
- How aggressive is the likely pace of loss?
- Can I consistently hit a realistic protein target?
- Am I resistance training?
- Am I tracking strength, waist, and body composition instead of using the scale alone?
That framework is more useful than trying to crown one molecule as universally “best for muscle.”
A Necessary Note On Gray-Market Retatrutide
Some people are already trying to get retatrutide from research-use-only or gray-market sellers because it is not yet FDA approved.
That is not a recommendation.
GLPLeanMass does not recommend that path because product identity, sterility, dose accuracy, storage conditions, and chain of custody are not assured. Interest in retatrutide will likely keep rising, but the safest public-facing position is still clear: investigational does not mean consumer-ready.
Why This Topic Still Matters Before Approval
Even before any future FDA decision, this topic is worth building now for three reasons:
- search demand is likely to grow as more people hear about retatrutide
- readers already compare semaglutide, tirzepatide, and retatrutide in the same mental bucket
- the body-composition angle is a more defensible GLPLeanMass lane than generic “which one helps you lose the most weight” content
That last point matters for the brand. We do not need to win the entire medication-comparison internet. We need to own the narrower question: what happens to lean mass, strength, and weight-loss quality?
Bottom Line
As of May 28, 2026, the cleanest evidence-based summary is this:
- semaglutide works
- tirzepatide probably works better for average weight loss
- retatrutide may work even better, but it is still investigational and not FDA approved
- the muscle-retention question is still more nuanced than the scale-weight question
If your actual goal is a better body-composition result, not just a lower number on the scale, then the highest-value move is still the same regardless of drug: protect protein, train against loss, and monitor more than body weight.
FAQ
Is retatrutide better than tirzepatide for weight loss?
It may be, but that is still an emerging answer rather than settled everyday clinical reality. The phase 2 and announced phase 3 obesity results are very strong, but retatrutide is still investigational as of May 28, 2026.
Which is best for preserving muscle: semaglutide, tirzepatide, or retatrutide?
That is not clearly established. Right now, the practical muscle-preservation levers still matter more than trying to rank the drugs as if one automatically solves lean-mass loss.
Is retatrutide approved yet?
No. As of May 28, 2026, retatrutide is not FDA approved.
Should I buy retatrutide from a research-use-only site?
No. GLPLeanMass does not recommend using research-use-only or gray-market sources for investigational compounds.
